Manufacture Advanced Medicine, Bioprocessing - Upstream & Downstream

Bioprocessing Revisited: Applying the Lessons from mAbs Production to Advanced Therapeutics Manufacturing

12/04/2024

sponsored by Repligen

Biotherapeutic manufacturers must move beyond traditional batch and fed-batch processing and look to adopt continuous approaches to increase dose production, reduce costs, and maintain consistent quality. Join a panel of experts from Repligen as we discuss how the lessons learned from monoclonal antibodies (mAbs) production can be applied to advanced therapeutic medicinal products (ATMPs) including gene therapies, cell therapies, nucleic acid-based therapies, oncolytics, vaccines, and exosomes.

Webinar Learning Objectives

Understand the innovative technologies and strategies that led to boosted mAbs productivity, reduced COGS, and improved quality.
Examine how scalable N perfusion and intensified fed-batch using N-1 perfusion in mAbs and viral vector production can lead to 3X improvements in space-time yield.
Learn how to overcome the unique challenges of advanced therapeutics, ensuring higher productivity, scalability, and cost-effectiveness in ATMP manufacturing.

View on demand

Email*

Choose a password*

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.